Inflammatory Skin Disease Summit

Explore the latest advancements and expert insights from ISDS 2025 held in New York, New York.

Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.

New long-term findings reveal guselkumab (TREMFYA) as the only IL-23 inhibitor effectively preventing joint damage in active psoriatic arthritis.

Dupilumab clears AD clinically and histologically, but deep immune profiling shows disease-memory T cells persist in the skin.

Benjamin Ungar, MD, shares groundbreaking insights on seborrheic dermatitis and emerging treatments in dermatology at ISDS 2025.

Neuroimmune modulation, including vagus nerve stimulation, is highlighted as a promising strategy for patients unresponsive to biologics.

Kilian Eyerich, MD, PhD, argues that classifying skin diseases by immune response patterns offers clearer therapeutic guidance than traditional morphology.

Michael Rosenblum’s team identified a previously underappreciated fibroblast subset that actively regulates inflammation, fibrosis, and microbial containment in the skin.

Therapeutic modulation of mitochondria offers a pathway to control multiple cytokine pathways simultaneously.

Chronic itching can reflect systemic disease, highlighting the importance of comprehensive assessment.

Robert Bissonnette, MD, presented tape-strip transcriptomics detecting meaningful steroid responses after just 1 day of therapy.

Kim explores the significance of inflammation in dermatology, revealing its connections to various diseases and the importance of focused research.

Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.